PRYaMOY INGIBITOR RENINA ALISKIREN - SAMOSTOYaTEL'NAYa STRATEGIYa KORREKTsII KARDIORENAL'NOGO SINDROMA PRI METABOLIChESKOM SINDROME I OZhIRENII


Cite item

Full Text

Abstract

Role of direct renin inhibitor aliskiren in halting the progression of chronic kidney disease in obesity and metabolic syndrome is discussed

About the authors

V V Fomin

E A Saginova

References

  1. Чазова И.Е., Мычка В.Б. Метаболический синдром. М., 2004
  2. Ting S.M., Nair H., Ching I. et al. Overweight, obesity and chronic kidney disease. Nephron. Clin. Pract. 2009; 112(3): c121-c127
  3. Nelson R., Antonetti I., Bisognano J.D., Sloand J. Obesity-related cardiorenal syndrome. J. Clin Hypertens. 2010; 12(1): 59-63
  4. Мухин Н.А., Фомин В.В., Сагинова Е.А. и др. Эндотелиальная дисфункция и поражение почек при ожирении. Вестник РАМН 2006; 12: 32 - 37
  5. Bravo P.E., Morse S., Borne D.M., Aguilar E.A., Reisin E. Leptin and hypertension in obesity. Vasc. Health Risk Manag. 2006; 2(2):163-169
  6. Fruhbeck G. The adipose tissue as a source of vasoactive factors. Сurr. Med. Chem. Cardiovasc. Hematol. Agents. 2004; 2: 197 - 208
  7. Sowers J.R., Epstein M., Frohlich E.D. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension. 2001; 37: 1053 - 1059
  8. Sarzani R., Salvi F., Dessì-Fulgheri P., Rappelli A. Renin-angiotensin system, natriuretic peptides, obesity, metabolic syndrome, and hypertension: an integrated view in humans. J. Hypertens. 2008; 26(5): 831-843
  9. Engeli S., Schling P., Gorzelniak K. et al. The adipose-tissue renin-angiotensin-aldosterone system: role in the metabolic syndrome? Int. J. Biochem. Cell Biol. 2003; 35(6): 807-825
  10. Nguyen G., Delarue F., Burcklé C. et al. Pivotal role of the renin/pro-renin receptor in angiotensin II production and cellular responses to renin. J. Clin. Invest/ 2002; 109:1417-1427
  11. Danser A.H.J., Deinum J. Renin, prorenin, and the putative prorenin receptor. Hypertension 2005; 46: 1069 - 1076
  12. Oliver J.A. Receptor mediated actions of renin and pro-renin. Kidney Int. 2006; 69: 13-15
  13. Huang Y., Wongamorntham S., Kasting J. et al. Renin increases mesangial cell transforming growth factor-beta1 and matrix proteins through receptor-mediated, angiotensin II-independent mechanisms. Kidney Int 2006;69:105-113
  14. Nguen G., Danser A.H.J. Prorenin and (pro)renin receptor: a review of available data from in vitro studies and experimental models in rodents. Exp. Physiol. 2008; 93 (Pt.5): 557 - 563
  15. Ichihara A., Suzuki F., Nakagawa T. et al. Prorenin receptor blockade inhibits development of glomerulosclerosis in diabetic angiotensin II type 1a receptor-deficient mice. J. Am. Soc. Nephrol. 2006; 17:1950-1961
  16. Kaneshiro Y., Ichihara A., Sakoda M. et al. Slowly progressive, angiotensin II-independent glomerulosclerosis in human (pro)rennin receptor-transgenic rats. J. Am. Soc. Nephrol. 2007; 18:1789-1795
  17. Krebs C., Hamming I., Sadaghiani S. et al. Antihypertensive therapy upregulates renin and (pro)renin receptor in the clipped kidney of Goldblatt hypertensive rats. Kidney Int. 2007; 72: 725-730
  18. He M., Zhang L., Shao Y. et al. Inhibition of renin/prorenin receptor attenuated mesangial cell proliferation and reduced associated fibrotic factor release. Eur. J. Pharmacol. 2009; 606(1-3): 155-161
  19. Fisher N.D.L., Hollenberg N.K. Renin inhibition: what are the therapeutic opportunities? J. Am. Soc. Nephrol. 2005; 16: 592 - 599
  20. Staessen J.A., Li Y., Richart T. Oral renin inhibitors. Lancet 2006; 368: 1449 - 1456
  21. Whaley-Connel A., Sowers J., Purkayastha D. et al. Combination therapy with aliskiren and hydrochlorothiazide decreases plasma renin activity and oxidative stress versus ramipril while reducing blood pressure in obese patients with stage 2 hypertension. J. Clin. Hypertens. 2010 ; 12(Suppl. 1) : A46
  22. Latini R., Masson S., Anand I. et al. The comparative prognostic value of plasma neurohormones at baseline in patients with heart failure enrolled in Val-HeFT. Eur Heart J. 2004; 25: 292 - 299
  23. Yeyati N.L., Adrogue H.J. Inappropriately high plasma renin activity accompanies chronic loss of renal function. Am. J. Nephrol. 1996; 16: 471 - 477
  24. Jordan J., Engeli S., Boye S.W. et al. Direct renin inhibition with aliskiren in obese patients with arterial hypertension. Hypertension. 2007; 49: 1047 - 1055
  25. Luetscher J.A., Kraemer F.B., Wilson D.M. et al. Increased plasma inactive renin in diabetes mellitus. A marker of microvascular comlications. N. Engl. J. Med. 1985; 312: 1412 - 1417
  26. Chiarelli F., Pomilio M., De Luca F.A. et al. Plasma prorenin levels may predict persistent microalbuminuria in children with diabetes. Pediatr. Nephrol. 2001; 16: 116 - 120
  27. Kelly D.J., Zhang Y., Moe G. et al. Aliskiren, a novel renin inhibitor, is renoprotective in a model of advanced diabetic nephropathy in rats. Diabetologia. 2007; 50(11): 2398-2404
  28. Pilz B., Shagdarsuren E., Wellner M. et al. Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension. 2005; 46(3): 569-576
  29. Parving H.H., Persson F., Lewis J.B., Lewis E.J., Hollenberg N.K.; AVOID Study Investigators. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N. Engl. J. Med. 2008; 358(23): 2433-2446
  30. Persson F et al. Renoprotective effects of direct renin inhibition compared to and in combination with maximum recommended dose of Irbesartan in patients with type 2 diabetes and albuminuria. Diabetologia 2008; 51 (Suppl 1): S492.
  31. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. Nephrol. Dial. Transplant. 2009; 24(5): 1663 - 1671
  32. Delea T.E., Sofrygin O., Palmer J.L. et al. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. J. Am. Soc. Nephrol. 2009; 20(10): 2205-2213

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies